What’s Next for Horizon Therapeutics Public Limited Company – Ordi (NASDAQ:HZNP) After Having More Shares Shorted?

Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) Logo

Investors sentiment decreased to 0.04 in 2019 Q2. Its down 1.95, from 1.99 in 2019Q1. It turned negative, as 195 investors sold Horizon Therapeutics Public Limited Company shares while 2 reduced holdings. 1 funds opened positions while 7 raised stakes. 4.39 million shares or 97.10% less from 151.47 million shares in 2019Q1 were reported.
Clarivest Asset Ltd Liability Company holds 226,881 shares or 0.12% of its portfolio. Eagle Asset Mgmt accumulated 2.69M shares or 0.33% of the stock. C Worldwide Group Holding A S holds 0.15% of its portfolio in Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) for 491,544 shares. Castleark Mngmt Limited Liability Co accumulated 0.34% or 362,980 shares. Jabodon Pt Com owns 187,808 shares. New York-based Knott David M has invested 0.51% in Horizon Therapeutics Public Limited Company (NASDAQ:HZNP). Gotham Asset Mgmt Ltd Liability Corporation has invested 0.08% in Horizon Therapeutics Public Limited Company (NASDAQ:HZNP). Usa Portformulas Corp owns 15,202 shares. King Luther Corporation reported 0.02% of its portfolio in Horizon Therapeutics Public Limited Company (NASDAQ:HZNP). Voloridge Inv Management Limited Liability Company stated it has 0.01% of its portfolio in Horizon Therapeutics Public Limited Company (NASDAQ:HZNP).

The stock of Horizon Therapeutics Public Limited Company – Ordi (NASDAQ:HZNP) registered an increase of 16.58% in short interest. HZNP’s total short interest was 8.87M shares in October as published by FINRA. Its up 16.58% from 7.61M shares, reported previously. With 1.85 million shares average volume, it will take short sellers 5 days to cover their HZNP’s short positions.

The stock increased 0.27% or $0.07 during the last trading session, reaching $26.39. About 496,272 shares traded. Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) has risen 42.39% since October 8, 2018 and is uptrending. It has outperformed by 42.39% the S&P500.

Horizon Pharma Public Limited Company, a biopharmaceutical company, engages in identifying, developing, acquiring, and commercializing medicines for the treatment of orphan diseases, arthritis, pain, and inflammation and inflammatory diseases in the United States and internationally. The company has market cap of $4.92 billion. The companyÂ’s marketed medicine portfolio consists of ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; RAVICTI and BUPHENYL/AMMONAPS to treat urea cycle disorders; PROCYSBI for the treatment of nephropathic cystinosis; QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients; and KRYSTEXXA to treat chronic refractory gout. It has a 75.19 P/E ratio. The Company’s products also include RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus, and multiple other indications; DUEXIS to treat signs and symptoms of osteoarthritis and rheumatoid arthritis; MIGERGOT for the treatment of vascular headache; PENNSAID 2% to treat pain of osteoarthritis of the knees; and VIMOVO for the treatment of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.

Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) Ratings Coverage

Among 3 analysts covering Horizon Pharma (NASDAQ:HZNP), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Horizon Pharma has $3600 highest and $3400 lowest target. $35.33’s average target is 33.88% above currents $26.39 stock price. Horizon Pharma had 6 analyst reports since April 20, 2019 according to SRatingsIntel. As per Wednesday, August 14, the company rating was upgraded by BMO Capital Markets.

More notable recent Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) news were published by: Fool.com which released: “Horizon Pharma PLC (HZNP) Q1 2019 Earnings Call Transcript – Motley Fool” on May 08, 2019, also Finance.Yahoo.com with their article: “Horizon Therapeutics Plc (HZNP) Chairman, President and CEO Timothy P Walbert Sold $1. … – Yahoo Finance” published on August 23, 2019, Fool.com published: “Why Horizon Pharma PLC Stock Is Spiking Today – Motley Fool” on November 08, 2018. More interesting news about Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) were released by: Seekingalpha.com and their article: “Horizon’s Past Biotech Purchase Has Paid Off In A Great Way – Seeking Alpha” published on March 08, 2019 as well as Seekingalpha.com‘s news article titled: “Horizon Pharma up 23% premarket on positive teprotumumab data – Seeking Alpha” with publication date: February 28, 2019.

Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.